{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:30:59Z","timestamp":1754152259375,"version":"3.41.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,21]]},"DOI":"10.7759\/cureus.88464","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T22:32:40Z","timestamp":1753137160000},"source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis Beyond the Skin: A Disease With Cardiovascular Risk"],"prefix":"10.7759","author":[{"given":"Maria","family":"Cristofori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 C","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel E","family":"Cort\u00e9s-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adipp","family":"Sall\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairo","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja A","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021, 21:170-3. 10.7861\/clinmed.2021-0257","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study","volume":"8","author":"Damiani G","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al.. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med (Lausanne). 2021, 8:743180. 10.3389\/fmed.2021.743180","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.11075","article-title":"Cardiovascular comorbidities in psoriasis (review)","volume":"23","author":"Branisteanu DE","year":"2022","unstructured":"Branisteanu DE, Nicolescu AC, Branisteanu DC, et al.. Cardiovascular comorbidities in psoriasis (review). Exp Ther Med. 2022, 23:152. 10.3892\/etm.2021.11075","journal-title":"Exp Ther Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868277","article-title":"Psoriasis and cardiovascular diseases: an immune-mediated cross talk?","volume":"13","author":"Orlando G","year":"2022","unstructured":"Orlando G, Molon B, Viola A, Alaibac M, Angioni R, Piaserico S. Psoriasis and cardiovascular diseases: an immune-mediated cross talk?. Front Immunol. 2022, 13:868277. 10.3389\/fimmu.2022.868277","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004591","article-title":"Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study","volume":"22","author":"Lin TL","year":"2025","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study. PLoS Med. 2025, 22:e1004591. 10.1371\/journal.pmed.1004591","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.774808","article-title":"Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis","volume":"12","author":"Cai J","year":"2021","unstructured":"Cai J, Cui L, Wang Y, Li Y, Zhang X, Shi Y. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol. 2021, 12:774808. 10.3389\/fphar.2021.774808","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2024.0064","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz U","year":"2024","unstructured":"Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024, 121:467-72. 10.3238\/arztebl.m2024.0064","journal-title":"Dtsch Arztebl Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S462797","article-title":"The role of interleukin 23\/17 axis in psoriasis management: a comprehensive review of clinical trials","volume":"17","author":"Potestio L","year":"2024","unstructured":"Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M. The role of interleukin 23\/17 axis in psoriasis management: a comprehensive review of clinical trials. Clin Cosmet Investig Dermatol. 2024, 17:829-42. 10.2147\/CCID.S462797","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60980","article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Ni R","year":"2024","unstructured":"Ni R, Zheng J, Varghese J, Kumar B. The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024, 16:e60980. 10.7759\/cureus.60980","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger JG","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, et al.. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024, 15:1331217. 10.3389\/fimmu.2024.1331217","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla NC","year":"2023","unstructured":"Brembilla NC, Boehncke WH. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023, 14:1186455. 10.3389\/fimmu.2023.1186455","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835671","article-title":"Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis","volume":"13","author":"Wang Y","year":"2022","unstructured":"Wang Y, Zang J, Liu C, Yan Z, Shi D. Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis. Front Immunol. 2022, 13:835671. 10.3389\/fimmu.2022.835671","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2020.15.R2","article-title":"The association between psoriasis and cardiovascular diseases","volume":"16","author":"Zwain A","year":"2021","unstructured":"Zwain A, Aldiwani M, Taqi H. The association between psoriasis and cardiovascular diseases. Eur Cardiol. 2021, 16:e19. 10.15420\/ecr.2020.15.R2","journal-title":"Eur Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.864185","article-title":"Endothelial dysfunction in psoriasis: an updated review","volume":"9","author":"Anyfanti P","year":"2022","unstructured":"Anyfanti P, Margouta A, Goulas K, Gavriilaki M, Lazaridou E, Patsatsi A, Gkaliagkousi E. Endothelial dysfunction in psoriasis: an updated review. Front Med (Lausanne). 2022, 9:864185. 10.3389\/fmed.2022.864185","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/00368504241287893","article-title":"Arterial function is preserved in successfully treated patients with psoriasis vulgaris","volume":"107","author":"Merzel \u0160abovi\u0107 EK","year":"2024","unstructured":"Merzel \u0160abovi\u0107 EK, Kraner \u0160umenjak T, Bo\u017ei\u010d Mijovski M, Jani\u0107 M. Arterial function is preserved in successfully treated patients with psoriasis vulgaris. Sci Prog. 2024, 107:368504241287893. 10.1177\/00368504241287893","journal-title":"Sci Prog"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick MS","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021, 77:1670-80. 10.1016\/j.jacc.2021.02.009","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016956","article-title":"Impact of psoriasis on mortality rate and outcome in myocardial infarction","volume":"9","author":"Karbach S","year":"2020","unstructured":"Karbach S, Hobohm L, Wild J, et al.. Impact of psoriasis on mortality rate and outcome in myocardial infarction. J Am Heart Assoc. 2020, 9:e016956. 10.1161\/JAHA.120.016956","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.829709","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study","volume":"9","author":"Liu L","year":"2022","unstructured":"Liu L, Cui S, Liu M, Huo X, Zhang G, Wang N. Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study. Front Cardiovasc Med. 2022, 9:829709. 10.3389\/fcvm.2022.829709","journal-title":"Front Cardiovasc Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.42694","article-title":"Derivation and internal validation of a disease-specific cardiovascular risk prediction model for patients with psoriatic arthritis and psoriasis","volume":"76","author":"Colaco K","year":"2024","unstructured":"Colaco K, Lee KA, Akhtari S, et al.. Derivation and internal validation of a disease-specific cardiovascular risk prediction model for patients with psoriatic arthritis and psoriasis. Arthritis Rheumatol. 2024, 76:238-46. 10.1002\/art.42694","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251337020","article-title":"Practical recommendations on cardiovascular risk evaluation in patients with psoriasis and psoriatic arthritis for dermatologists, rheumatologists, and primary care physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network","author":"Sheth S","year":"2025","unstructured":"Sheth S, Inestroza K, Merola JF, Weber B, Garshick M. Practical recommendations on cardiovascular risk evaluation in patients with psoriasis and psoriatic arthritis for dermatologists, rheumatologists, and primary care physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. J Psoriasis Psoriatic Arthritis. 2025, 24755303251337020. 10.1177\/24755303251337020","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.008","article-title":"Using guidelines of care to lower cardiovascular risk in patients with psoriasis","volume":"42","author":"Song WB","year":"2024","unstructured":"Song WB, Soffer DE, Gelfand JM. Using guidelines of care to lower cardiovascular risk in patients with psoriasis. Dermatol Clin. 2024, 42:417-28. 10.1016\/j.det.2024.02.008","journal-title":"Dermatol Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S328572","article-title":"Comorbidity in adult psoriasis: considerations for the clinician","volume":"12","author":"Daugaard C","year":"2022","unstructured":"Daugaard C, Iversen L, Hjuler KF. Comorbidity in adult psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022, 12:139-50. 10.2147\/PTT.S328572","journal-title":"Psoriasis (Auckl)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010056","article-title":"Pathophysiology and treatment of psoriasis: from clinical practice to basic research","volume":"17","author":"Gao Y","year":"2025","unstructured":"Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z, Yu H. Pathophysiology and treatment of psoriasis: from clinical practice to basic research. Pharmaceutics. 2025, 17:10.3390\/pharmaceutics17010056","journal-title":"Pharmaceutics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee HJ","year":"2023","unstructured":"Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023, 24:10.3390\/ijms241713313","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020, 323:1945-60. 10.1001\/jama.2020.4006","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1724250","article-title":"Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites","volume":"32","author":"Hoegsberg T","year":"2021","unstructured":"Hoegsberg T, Iversen L, Lange MM, et al.. Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. J Dermatolog Treat. 2021, 32:916-21. 10.1080\/09546634.2020.1724250","journal-title":"J Dermatolog Treat"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets CA","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al.. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021, 84:432-70. 10.1016\/j.jaad.2020.07.087","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/nu15153387","article-title":"Psoriasis and vitamin D: a systematic review and meta-analysis","volume":"15","author":"Formisano E","year":"2023","unstructured":"Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and vitamin D: a systematic review and meta-analysis. Nutrients. 2023, 15:10.3390\/nu15153387","journal-title":"Nutrients"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.6525","article-title":"Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review","volume":"103","author":"Amiri D","year":"2023","unstructured":"Amiri D, Schwarz CW, Gether L, Skov L. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2023, 103:adv00890. 10.2340\/actadv.v103.6525","journal-title":"Acta Derm Venereol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50249","article-title":"Excimer laser system: the revolutionary way to treat psoriasis","volume":"15","author":"Alyoussef A","year":"2023","unstructured":"Alyoussef A. Excimer laser system: the revolutionary way to treat psoriasis. Cureus. 2023, 15:e50249. 10.7759\/cureus.50249","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79097","article-title":"Therapeutic advancements in the management of psoriasis: a clinical overview and update","volume":"17","author":"Qasem SF","year":"2025","unstructured":"Qasem SF, Ashkanani H, Ali A. Therapeutic advancements in the management of psoriasis: a clinical overview and update. Cureus. 2025, 17:e79097. 10.7759\/cureus.79097","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00409-4","article-title":"Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature","volume":"10","author":"Balak DM","year":"2020","unstructured":"Balak DM, Gerdes S, Parodi A, Salgado-Boquete L. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. Dermatol Ther (Heidelb). 2020, 10:589-613. 10.1007\/s13555-020-00409-4","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2495986","article-title":"Review on recommendations on the use of biologic therapy for the management of moderate-severe psoriasis in Saudi Arabia: an expert opinion","volume":"25","author":"Fatani M","year":"2025","unstructured":"Fatani M, Aldugaither A, Alaithan M, et al.. Review on recommendations on the use of biologic therapy for the management of moderate-severe psoriasis in Saudi Arabia: an expert opinion. Expert Opin Biol Ther. 2025, 25:599-606. 10.1080\/14712598.2025.2495986","journal-title":"Expert Opin Biol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.057","article-title":"The efficacy, safety and longevity of biologic treatments in pediatric and adult psoriasis patients: a comparative multi-center, real-life study","volume":"37","author":"\u00c7ak\u0131c\u0131 \u00d6A","year":"2025","unstructured":"\u00c7ak\u0131c\u0131 \u00d6A, Topkarc\u0131 Z, G\u00fcne\u015f BY, Onsun N, Se\u00e7kin D, Ergun T. The efficacy, safety and longevity of biologic treatments in pediatric and adult psoriasis patients: a comparative multi-center, real-life study. Ann Dermatol. 2025, 37:114-21. 10.5021\/ad.24.057","journal-title":"Ann Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030076","article-title":"Therapeutic advances in psoriasis: from biologics to emerging oral small molecules","volume":"13","author":"Ferrara F","year":"2024","unstructured":"Ferrara F, Verduci C, Laconi E, et al.. Therapeutic advances in psoriasis: from biologics to emerging oral small molecules. Antibodies (Basel). 2024, 13:10.3390\/antib13030076","journal-title":"Antibodies (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391091-psoriasis-beyond-the-skin-a-disease-with-cardiovascular-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T22:32:41Z","timestamp":1753137161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391091-psoriasis-beyond-the-skin-a-disease-with-cardiovascular-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.88464","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}